Sigyn Therapeutics (OTCMKTS:SIGY) Posts Earnings Results

Sigyn Therapeutics (OTCMKTS:SIGY) released its earnings results on Thursday. The company reported ($0.42) EPS for the quarter, Zacks reports.

Sigyn Therapeutics Stock Up 6.4%

Shares of OTCMKTS:SIGY traded up $0.00 on Thursday, hitting $0.03. 4,007 shares of the company traded hands, compared to its average volume of 95,084. The company has a market cap of $63,500.00, a PE ratio of -0.01 and a beta of -0.08. Sigyn Therapeutics has a 52 week low of $0.01 and a 52 week high of $5.00. The stock has a 50 day simple moving average of $0.04 and a 200-day simple moving average of $0.30.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.